pPLUS® AAV-Helper is a novel plasmid helper designed for AAV production. This plasmid has been optimized for triple transfection of HEK293 cells in s...
Meet Polyplus at booth #21 during the Biprocessing Summit Europe in Barcelona, Spain from 19th - 21st March 2024. Don't miss the opportunity to hear our talk by our expert Paul Giroud on the tools that are available to improve AAV productivity and quality in the year 2024 and our poster presentations on Novel engineered pHelper plasmid to improve yield and quality of several AAV serotypes in suspension cell culture systems.
Paul Giroud – Scientific Support Specialist
Talk : In 2024, what tools are available to improve AAV productivity and quality | Wednesday 20 March, 3:50 – 4:20 PM
Talk Summary : Enhancing AAV productivity and quality is key to enable more Gene Therapy products to reach commercialization. There are several approaches to improve productivity, of which a cost-effective approach whereby early on during process development, multiple parameters can be optimized thanks to DOE at both Upstream and Downstream levels. Combining using latest generation reagents and plasmid engineering tools with DOE can have a significant and positive impact on process efficiency.
Novel engineered pHelper plasmid to improve yield and quality of several AAV serotypes in suspension cell culture systems
Harnessing rAAVs as viral vectors for therapeutic transgene delivery still requires improvements in yields and specificity to lower vector doses, and therefore manufacturing cost, as well as to improve patient safety. To this end, our research is focused on developing novel technologies to ensure manufacturing of high yielding rAAV particles using transient transfection, as well as enhancing features of rAAV vectors that act on the overall size of packaged material and specificity of delivery. Here we present our state-of-the art approach to design new helper plasmids (phelpers) with the aim of improving both the infectiosity (TU/mL) and the quality (full/empty ratio) of the viral particle obtained from suspension cultures. We took the opportunity to exploit our proprietary DNA assembly method technology to explore the synergies of multiple genetic features modularly assembled in synthetic plasmids. Comparison of the biological activity of several versions of rationally designed pHelpers led us to identify the optimal configuration able to outperform existing helper plasmids in every tested bioproduction conditions. Our expertise in DNA plasmid design and assembly together with our scalable transfection solutions for rAAV manufacturing gives us the potential to improve both productivity and specificity of gene therapy products.
Discover Our Applications
Cell & Gene Therapy
Success of Gene and Cell Therapies is dependent on efficient production of viral vectors that require optimized transfection reagents and viral vector engineering
RNA/DNA in vivo delivery is the most powerful alternative to viral vectors for nucleic acid-based therapies. They offer substantial advantages in terms of reliability,safety and costs for nucleic-acid based therapies
Broad range of solutions is needed for manufacturing of functional proteins or antibodies at the desired scale in bacteria, yeast and mammalian cell expression systems
Optimised plasmid engineering and specific transfection reagents are key to enable protein expression in a wide range of adherent and suspension mammalian cell types